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ABSTRACT
OBJECTIVE: The objective of this selective evidence based medicine review is to determine
whether or not “Is radiofrequency energy a safe and effective treatment for reducing symptoms
of gastroesophageal reflux disease in patients 18 years or older?”
STUDY DESIGN: Review of two double-blind, randomized control trials and one double-blind,
randomized cross-over study published between 2003 and 2012. All studies were published in
the English language in peer reviewed journals.
DATE SOURCES: Two randomized control trials and one randomized cross-over study were
found using PubMed.
OUTCOMES MEASURED: The outcomes measured include changes in GERD symptom scores
for fourteen symptoms, improvement of GERD symptoms based on a GERD HRQL
questionnaire, decrease in heartburn based on a 6 point Likert scale, and GERD health related
quality of life based on a 6 point Likert scale.
RESULTS: Arts et al (2012) demonstrated a significant reduction in GERD symptom scores
after treatment with radiofrequency energy with a p value of < 0.005. Aziz et al (2010)
demonstrated a significant reduction in GERD symptoms after treatment with radiofrequency
energy with a p value of < 0.05. Corley at al (2003) demonstrated a significant decrease in both
heartburn and GERD health related quality of life after treatment with radiofrequency energy
with a p value of 0.05 and 0.03, respectively. A noted side effect in two of the studies include
chest pain.
CONCLUSIONS: Results of the three studies demonstrate that radiofrequency energy is an
effective treatment for reducing the symptoms of gastroesophageal reflux disease. Two studies
assessing chest pain following radiofrequency energy demonstrated that the safety of
radiofrequency energy is inconclusive and requires further investigation.
KEY WORDS: gastroesophageal reflux disease, GERD, radiofrequency energy, Stretta
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INTRODUCTION
Gastroesophageal reflux disease, commonly known as GERD, is a chronic condition that
occurs when the lower esophageal sphincter inappropriately relaxes or is weakened. This defect
allows stomach contents and acid to flow back into the esophagus.7 The irritation from the acid
and stomach contents on the esophageal lining is what causes the symptoms of GERD, which
can greatly impact a person’s quality of life. GERD is a common condition. It is estimated that
GERD affects 15% to 20% of adults in the United States.4 There are approximately 8.9 million
ambulatory healthcare visits and 4.7 million hospitalizations due to GERD with an annual health
care cost of 9.8 million dollars.3,5
The relaxation or weakening of the lower esophageal sphincter can be caused by
numerous things such as increased abdominal pressure (obesity, pregnancy), medications
(calcium channel blockers, antihistamines, sedatives, antidepressants, asthma medications),
smoking, and hiatal hernias.3 The most common symptoms of GERD include substernal
heartburn and regurgitation. Other symptoms include chest pain, nausea, vomiting, abdominal
pain, dysphagia, dental erosions, and a chronic cough.4,7 There are numerous complications of
GERD including esophagitis, esophageal strictures, respiratory problems, and Barrett’s
metaplasia.7 Barrett’s metaplasia can progress to esophageal adenocarcinoma, which occurs at a
yearly development rate of 0.1% to 0.3% per year.4
GERD is treated with both lifestyle modifications and medications. Lifestyle
modifications include avoiding foods and beverages that exacerbate heartburn and further
weaken the lower esophageal sphincter (fried and fatty food, chocolate, peppermint, alcohol,
coffee, vinegar, tomato sauce, citrus, etc.), avoiding aspirin and NSAIDs, eating smaller portions,
not eating before bedtime, raising the head of the bed, losing weight, and smoking cessation.6
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Medications include antacids, H2 receptor antagonists, and proton pump inhibitors. Antacids and
H2 receptor antagonists are used for mild symptoms of GERD. Proton pump inhibitors are the
treatment of choice for moderate to severe symptoms of GERD.4,6 Unfortunately, patients with
GERD may not have a sufficient response to high dose PPI medications.1 These medications can
cause unbearable side effects and are also expensive, ranging anywhere between $2,000 to
$3,000 per year.3,9 Using radiofrequency energy, which is called the Stretta procedure, is an
alternative treatment option for patients with symptoms of GERD. It is conducted via a
minimally invasive procedure with an endoscope that applies controlled radiofrequency energy
to the lower esophageal sphincter.1,2,3 It promotes symptom relief and decreases the need of PPI
medication in patients with GERD by improving the antireflux barrier and augmenting the lower
esophageal pressure.1,2
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or
not “Is radiofrequency energy is a safe and effective treatment for reducing symptoms of
gastroesophageal reflux disease in patients 18 years or older?”

METHODS
Criteria: This selective evidence based medicine review evaluates two double-blind,
randomized control trials and one double-blind, cross-over study chosen based on population,
intervention, comparison group, and outcomes measured. The selected population of interest was
patients 18 years or older with a diagnosis of GERD. The intervention in these three studies was
radiofrequency energy delivered to the lower esophageal sphincter and gastroesophageal
junction. The treatment group receiving radiofrequency energy was compared to a group
receiving a sham procedure. The outcomes measured in these three studies included a decrease in
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heartburn, improvement or changes in GERD symptoms after radiofrequency energy, and the
effect on GERD health related quality of life.
Data Sources: The key words “gastroesophageal reflux disease,” “GERD,” “radiofrequency
energy,” and “Stretta” were searched on PubMed to find articles both relevant to the clinical
question and ones that included patient oriented outcomes. All articles were published in the
English language between 2003 and 2012 in peer reviewed journals. The inclusion criteria
included double-blind studies published after 2000 and exclusion criteria included patients under
18 years old. The statistics used and reported in this selective evidence based medicine review
include p-values, numbers needed to harm (NNH), numbers needed to treat (NNT), change in
mean from baseline, and confidence intervals.
Table 1 – Demographics & Characteristics of Included Studies
Study

Type

Arts,
2012
(1)

Doubleblind,
randomized
cross-over
study

#
Pts
22

Age
(years)
47 ± 12

Aziz,
2010
(2)

Double36
blind,
randomized
control trial

Sham:
32.0 ±
8.3 (22
to 48)
Tx:
36.7 ±
9.5 (24
to 50)

Inclusion
criteria
Long standing
history of
GERD,
typical GERD
symptoms,
response to
high dose PPI,
pathological
esophageal
pH
monitoring
> 18 y/o,
heartburn or
regurgitation
> 6 months,
GERD HRQL
score >18
when
medication
stopped,
HRQL score
of ≤ 10 on

Exclusion
criteria
< 18 y/o, hiatal
hernia,
Barrett’s,
erosive
esophagitis,
absent
peristaltic
contractions on
manometry,
coagulation
disorders
Hiatal hernia,
pregnancy, poor
surgical
candidate,
esophagitis,
Barrett’s
metaplasia or
dysplasia,
collagen
vascular
disease,

W/D

Interventions

Not
noted

Radiofrequency
energy
delivered
through four
needle
electrodes to the
region of the
LES

Not
noted

Single session
Stretta
procedure
(radiofrequency
energy)
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Corley,
2003
(3)

Double64
blind,
randomized
control trial

Sham:
52 ± 15
Tx:
45 ± 12

medication,
normal LES
relaxation,
abnormal acid
exposure, no
esophagitis
Heartburn or
regurgitation,
responsive to
daily
medication,
>18 y/o,
abnormal
esophageal
acid, normal
esophageal
peristalsis,
normal
sphincter
relaxation

autoimmune
disease, severe
dysphagia,
previous
esophageal or
gastric surgery
Hiatal hernia,
erosive
esophagitis,
Barrett’s,
extraesophageal
manifestations
of GERD,
coagulation
disorders,
mechanical
prostheses,
prominent
dysphagia,
unstable
disorders

8

Radiofrequency
energy delivery
to the GEJ

OUTCOMES MEASURED
All of the outcomes measured in this selective evidence medicine based review include
patient oriented evidence. These outcomes include change in GERD symptom scores,
improvement of GERD symptoms, improvement in the symptom of heartburn, and effect on
GERD health related quality of life. The Arts et al double-blind, randomized cross-over trial
measures changes in GERD symptom scores prior to and three months after the radiofrequency
energy treatment. Fourteen typical and atypical symptoms (heartburn, food regurgitation, acid
regurgitation, nausea, vomiting, chest pain, dysphagia, odynophagia, coughing, choking,
dyspnea, wheezing, hoarseness, and throat ache) were scored by the patient on a scale from zero
to three. Rating the symptom a three indicated that it interfered with daily activities and rating it
a zero meant the symptom was not present. All of the symptom scores were added together for a
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maximum cumulative score of 24. The data was reported as a mean change in baseline with a
standard deviation.1
The Aziz et al double-blind, randomized control trial measured improvement of GERD
symptoms. This was assessed based on a GERD health related quality of life (HRQL)
questionnaire. The baseline GERD HRQL scores were compared with scores both 6 and 12
months after radiofrequency energy treatment. The data was reported as a mean change in
baseline with a standard deviation.2
The Corley et al double-blind, randomized control trial measured a decrease in the
symptom of heartburn and GERD health related quality of life for multiple different symptoms.
Both were measured based via a six point Likert scale ranging from no symptoms to
incapacitating symptoms. The data was reported as both a mean change in baseline with standard
deviation and dichotomous data.3
RESULTS
This selective evidence based medicine review evaluates radiofrequency energy as a
treatment for GERD. The results of these studies were presented in both continuous and
dichotomous data: Arts et al presented continuous data, Aziz et al presented continuous and
dichotomous data, and Corley et al presented continuous and dichotomous data. All three studies
were randomized with concealment to randomization. All of the patients, clinicians, and study
workers were kept blind to which patients were in the treatment group for the duration of the
study.
Arts et al is a double-blind, randomized cross-over study that assesses the efficacy of
radiofrequency energy applied to the region of the gastroesophageal junction and lower
esophageal sphincter in adults who are 18 years or older with a long-standing history of GERD.
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The treatment group was compared to a sham procedure. This study involved twenty-two
patients divided evenly into two groups of eleven participants. One group was placed in the
radiofrequency energy group initially and the other group placed in the sham procedure first. To
qualify as a cross-over study, the participants received the opposite procedure three months after
the initial procedure. Symptom scores of the participants were evaluated both before and 3
months after the initial procedure for improvement. The symptom scores were obtained via
patient reports for fourteen typical and atypical symptoms (all scored on a scale from 0 to 3 for a
maximum score of 24) and continuous data was reported as mean change from baseline. The
mean change from baseline for the radiofrequency energy treatment group was 14.7 +/- 1.5
before the procedure to 8.3 +/- 1.9 at three month follow up. The mean change from baseline for
the sham procedure group was 16.1 +/- 2.5 before procedure to 15.6 +/- 2.2 at three month
follow up. At the conclusion of the study, it was determined there was a significant decrease in
symptom scores of GERD with a statistically significant p-value of < 0.005.1
Table 2 – GERD Symptom Scores at Baseline and 3 Month Follow Up
Baseline
3 Month Follow Up
Radiofrequency Energy
14.7 +/- 1.5
8.3 +/- 1.9
Procedure
Sham Procedure
16.1 +/- 2.5
15.6 +/- 2.2
Aziz et al is a double-blind, randomized control trial that assesses the efficacy and safety
of radiofrequency energy to the gastroesophageal junction in adults who are 18 years or older.
The treatment group was compared to a sham procedure. Thirty-six participants were placed into
one of three groups: twelve patients in a single radiofrequency energy procedure group, twelve
patients in a sham procedure group, and twelve patients in a two-series radiofrequency energy
group. For the purpose of this selective evidence based medicine review, the single
radiofrequency energy and the sham groups will be focused on. The study measured
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improvement of GERD symptoms based on a GERD related health quality of life questionnaire
at 6 and 12 months after the procedure. Only the twelve month follow up results were presented
as mean change from baseline. The mean change in baseline for the single radiofrequency energy
treatment group was 29.6 +/- 3.9 before treatment to 14.7 +/- 4.8 at twelve month follow up. The
mean change from baseline for the sham group was 30.3 +/- 3.8 before the procedure to 24.8 +/4.9 at twelve month follow up. At the conclusion of the study, it was determined there was a
significant decrease in GERD symptoms with a statistically significant with a p-value of < 0.05.2
Table 3 – Improvement of GERD Symptoms at Baseline and 12 Month Follow Up
Baseline
12 Month Follow Up
Single Radiofrequency Energy
29.6 +/- 3.9
14.7 +/- 4.8
Procedure
Sham Procedure
30.3 +/- 3.8
24.8 +/- 4.9
Corley et al is a double-blind, randomized control trial that assesses efficacy and safety of
radiofrequency energy to the gastroesophageal junction in adults who are 18 years or older. The
treatment group was compared to a sham procedure. Sixty-four patients with GERD were
randomly assigned to a radiofrequency energy group (35 patients) or a sham group (29 patients).
The study measured a decrease in the symptom of heartburn based on a 6 point Likert scale
ranging from no symptoms to incapacitating symptoms. The decrease in the symptom of
heartburn was reported as both continuous and dichotomous data at 6 month follow up. The
mean change in baseline for patients in the radiofrequency energy group was -1.6 (95%
confidence interval of -1.1 to -2.2) compared to a mean change in baseline of -0.6 (95%
confidence interval of 0.1 to -1.2, p = 0.01) in the sham procedure group. At six month follow
up, 61% of patients in the radiofrequency energy group and 33% of patients in the sham
procedure group were without heartburn symptoms. This was determined to be statistically
significant with a p-value value of 0.05.3 The RBI was determined to be 85% and the ABI was
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determined to be 28%. Numbers needed to treat was determined to be 4. Table 4 displays the
effectiveness of radiofrequency energy in decreasing the symptom of heartburn for this study.
Table 4 – Effectiveness of Radiofrequency Energy at Reducing Symptom of Heartburn
Sham
Radiofrequency Relative
Absolute
Number
Procedure Energy
Benefit
Benefit
Needed to
(CER)
Procedure
Increase
Increase (ABI) Treat (NNT)
(EER)
(RBI)
Corley
.33
.61
.61.61-.33=.28
1/.28=3.57 = 4
(2003)
.33/.33=.85
Corley at al also evaluated improvement of GERD health related quality of life scores for
multiple symptoms based off of a 6 point Likert scale ranging from no symptoms to
incapacitating. The improvement of GERD health related quality of life was reported as both
dichotomous and continuous data at 6 month follow up. The mean change in baseline for patients
in the radiofrequency energy group was -13 (95% confidence interval of -9 to -17) compared to a
mean change in baseline of -3 (95% confidence interval of -8 to 2, p = 0.003) in the sham
procedure group. At six month follow up, 61% of patients in the radiofrequency energy group
and 30% of patients in the sham procedure group had more than a 50% improvement in their
GERD health related quality of life score. This was determined to be statistically significant with
a p-value of 0.03.3 The RBI was determined to be over 100% and the ABI was determined to be
31%. Numbers needed to treat was determined to be 4. Table 5 displays the effectiveness of
radiofrequency energy in improving GERD health related quality of life scores.
Table 5 – Effectiveness of Radiofrequency Energy on GERD Health Related Quality of Life
Sham
Radiofrequency Relative
Absolute
Number
Procedure Energy
Benefit
Benefit
Needed to
(CER)
Procedure
Increase
Increase (ABI) Treat (NNT)
(EER)
(RBI)
Corley
.30
.61
.61.61-.30=.31
1/.31=3.22 = 4
(2003)
.30/.30=1.03
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For this selective evidence based medicine review, the common side effect of chest pain
was evaluated. Aziz et al and Corley et al evaluated chest pain after treatment with single
radiofrequency energy or sham procedure. Aziz et al determined that 58% of patients had chest
pain following radiofrequency energy procedure and 16.6% of patients had chest pain following
sham procedure.2 Corley et al determined that 11% of patients had chest pain following
radiofrequency energy procedure and 0% of patients had chest pain following sham procedure.3
Table 6 indicates the number of patients who had chest pain after receiving treatment with either
the radiofrequency energy or the sham procedure.
Table 6 – Safety of Radiofrequency Energy from Selected Studies: NNH
Study Patients
Patients with
Relative Risk
Absolute Risk
with Chest Chest Pain
Increase (RRI)
Increase
Pain
following
(ARI)
following
Radiofrequency
Sham
Energy
Procedure
Procedure
(CER)
(EER)
Aziz
.166
.58
.58-.166/.58 = .71 .58-.166 = .41
(2010)
Corley 0
.11
.11-0/.11 = 1
.11 – 0 = .11
(2003)

Numbers
Needed to
Harm (NNH)

1/.41 = 2.43 =
3
1/.11 = 9.09 =
10

DISCUSSION
The radiofrequency energy procedure that is offered in the United States is called the
Stretta system. This system was approved by the Food and Drug Administration in 2000.9
According to Vanderbilt University Medical Center, this endoscopic procedure may cost
anywhere from $7,500 to $10,000.9 Unfortunately, there is no frank answer as to whether
insurance will cover the Stretta procedure. However, Aetna determined that the Stretta procedure
was experimental and investigational based on a review of the current clinical information. Aetna
also states that the patient’s medical claim determines whether or not a particular medical
procedure is covered.10
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The Stretta System is specifically used to coagulate tissue in the region of the lower
esophageal sphincter and gastroesophageal junction for the treatment of gastroesophageal reflux
disease.8 Contraindications to the Stretta System include patients younger than 18 years old,
pregnancy, patients that do not have GERD, patients with a hiatal hernia larger than 2
centimeters, patients with achalasia, patients who have incomplete lower esophageal sphincter
relaxation after swallowing, and patients who are poor surgical candidates.8 The Stretta System
has not been studied in patients who have an implant that might be conductive with the
radiofrequency energy near the lower esophageal sphincter, patients with a normal twenty-four
hour pH study, patients with GERD symptoms that are unresponsive to proper anti-secretory
medication, Barrett’s metaplasia, active esophagitis that is grade three or four by Savary-Miller
criteria, patients who have risk factors for endocarditis, patients with esophageal bleeding or
dysphagia, patients who have untreated or unstable hypertension, diabetes mellitus, heart disease,
or collagen vascular disease, patients on steroids, patients who are immunosuppressed, patients
with a cardiac pacemaker, and patients who have coagulation abnormalities or are on
anticoagulation therapy.8 There are complications that may occur with radiofrequency energy
when treating GERD including bleeding, bloating, chest pain, difficulty belching, dysphagia,
epigastric pain, laceration of the esophageal mucosa, fever, perforation, pharyngitis, vomiting,
achalasia, prolonged gastric emptying, dental injury, dyspnea, infection, injury to the larynx, and
worsening of GERD.8
All three studies included in this selective evidence based medicine review demonstrated
limitations. Sample size was the main limitation. Arts et al had a sample size of twenty-two, Aziz
et al had a sample size of thirty-six, and Corley et al had a sample size of sixty-four.1,2,3 Corley
et al also had a considerable difference in the number of patients in the treatment group (35
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patients) and the number of patients in the sham group (29 patients).3 Another limitation was a
moderate dropout rate. For instance, Corley et al began their study with sixty-four patients and
ended with fifty-six.3
CONCLUSIONS
All three studies successfully demonstrated that there is a significant decrease in
symptoms of gastroesophageal reflux disease following treatment with radiofrequency energy.
Therefore, radiofrequency energy is an effective alternative treatment for reducing the symptoms
of GERD in patients who are 18 years or older. However, the two studies that assessed chest pain
following radiofrequency energy yielded inconclusive results. Due to this inconsistency, further
studies are warranted to assess the potential side effect of chest pain following treatment with
radiofrequency energy. It is also important to follow these patients for a longer period of time in
order to assess whether or not symptoms of GERD will return or if radiofrequency energy could
potentially be curative for patients with GERD. Since these three studies compared
radiofrequency energy to a sham procedure, it would be important to create a study comparing
radiofrequency energy to another treatment modality, such as long term proton pump inhibitors
or a surgical anti-reflux procedure, to see which method of treatment would be superior for
treating symptoms of GERD.
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